STC Technologies Receives FDA Clearance for Histofreezer(R) Portable Cyrosurgical System

Strategic Insights -

STC Technologies, Inc. (STC) has announced that it has received clearance from the Food & Drug Administration (FDA) to market its Histofreezer(R) Portable Cyrosurgical System for the treatment of actinic keratoses and lentigo, common premalignant skin tumors and age spots, respectively. This clearance marks a significant milestone for STC, as its Histofreezer(R) System has proven to be a safe, effective, and economical treatment for various skin lesions, including common and plantar warts. The FDA clearance will enable primary-care physicians to treat these conditions in their offices, eliminating the need for patients to visit dermatologists.

Key Takeaways:

  • STC Technologies has received FDA clearance to market its Histofreezer(R) Portable Cyrosurgical System for the treatment of actinic keratosis and lentigo.
  • The Histofreezer(R) System has been shown to be a safe, effective, and economical alternative to liquid nitrogen for treating various skin lesions, including common and plantar warts.
  • Actinic keratosis is a growing problem among the aging population, with approximately 30,000 to 120,000 people facing the risk of it developing into a cancerous lesion each year.
  • Steve Townes, Business Unit Manager for the Histofreezer(R) product line, stated that the clearance allows primary-care physicians to treat actinic keratosis and lentigo in their offices, reducing the need for patients to visit dermatologists.
  • STC had previously received FDA clearance for the Histofreezer(R) kit for the treatment of various skin abnormalities, including verruca vulgaris, verruca plantaris, and condyloma acuminata.
  • The Histofreezer(R) System has been named to INC. magazine's list of the 500 fastest growing, privately held companies in America in 1987 and 1990.

Statistics:

  • Approximately 30,000 to 120,000 people face the risk of actinic keratosis developing into a cancerous lesion each year.
  • The Histofreezer(R) System has been shown to be a safe, effective, and economical alternative to liquid nitrogen for treating various skin lesions.
  • STC has been named to INC. magazine's list of the 500 fastest growing, privately held companies in America in 1987 and 1990.
  • STC has developed, manufactures, and markets proprietary clinical diagnostic tests and medical devices for use in clinical labs, physicians' offices, and work-site testing.

Sources:

  • PRNewswire, July 19 (no date mentioned) - STC Technologies, Inc. Receives Clearance from FDA to Market Histofreezer(R) Portable Cyrosurgical System